• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 54Ipsilateral breast tumour recurrence model: high costs

RegimenCost (£)QALYICER (£)Net benefits (£)
λ = £20,000Rankλ = £30,000Rank
12-month interval
No surveillance157812.830255,0219383,32011
Mammography alone386913.0769309257,6522388,4131
Mammography + clinical531713.084179,674256,3658387,2066
MRI + clinical11,76813.098449,596250,20213381,18612
18-month interval
No surveillance157812.830255,0219383,32011
Mammography alone340013.0538164257,6621388,1932
Mammography + clinical445413.06495,002256,8307387,4714
MRI + clinical910713.085225,253252,59012383,43810
24-month interval
No surveillance157812.830255,0219383,32011
Mammography alone312413.0327638257,5233387,8463
Mammography + clinical398713.04665,386256,9245387,3795
MRI + clinical775213.071147,255253,67011384,3819
36-month interval
No surveillance157812.830255,0219383,32011
Mammography alone292913.0147345257,3484387,4863
Mammography + clinical367913.02851,600256,8886387,1727
MRI + clinical691913.058110,989254,23210384,8088

From: 7, Economic evaluation

Cover of The Clinical Effectiveness and Cost-Effectiveness of Different Surveillance Mammography Regimens After the Treatment for Primary Breast Cancer: Systematic Reviews, Registry Database Analyses and Economic Evaluation
The Clinical Effectiveness and Cost-Effectiveness of Different Surveillance Mammography Regimens After the Treatment for Primary Breast Cancer: Systematic Reviews, Registry Database Analyses and Economic Evaluation.
Health Technology Assessment, No. 15.34.
Robertson C, Arcot Ragupathy SK, Boachie C, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.